MEDP — Medpace Holdings, Inc.

Medpace (MEDP) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $707.3 million, up 17.2% year-over-year (YoY).
• Year-to-Date Revenue: $1.41 billion, a 21.7% increase YoY.
• EBITDA: $153.4 million, a 17.6% increase from $130.5 million in Q2 2025.
• EBITDA Margin: 21.7%, slightly up from 21.6% YoY; year-to-date margin at 21.4%, flat YoY.
• Net Income: $121.4 million, up 34.5% YoY; year-to-date net income at $245.2 million, a 19.7% increase.
• Net Income per Diluted Share: $4.25 for the quarter, compared to $3.10 in Q2 2025.
• Net New Business Awards: $795.7 million, a 28.2% increase YoY, with a net book-to-bill ratio of 1.13x.
• Ending Backlog: Approximately $3 billion, up 4.9% YoY; projected revenue conversion from backlog in the next 12 months is $1.96 billion.
• Cash Flow from Operations: $162 million; cash at quarter-end was $502.7 million.
• Share Repurchases: 706,000 shares repurchased for $294.7 million; $527 million remaining under the repurchase program.

2. Strategic Updates and Business Highlights

• The business environment in Q2 was strong, with well-managed cancellations and record net bookings.
• RFPs (Requests for Proposals) increased both sequentially and YoY, indicating a robust pipeline of opportunities.
• Oncology trials have seen a resurgence, contributing over half of the overall bookings, while the metabolic segment has seen a decline.
• Initiatives to improve win rates have been implemented, contributing to strong performance in Q1 and Q2.
• The company is positioning itself for growth in 2027, with a focus on diversifying its client base to mitigate customer concentration risks.

3. Forward Guidance and Outlook

• 2026 Total Revenue Guidance: Expected in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025.
• 2026 EBITDA Guidance: Projected between $618 million and $642 million, reflecting growth of 10.8% to 15.1% YoY.
• Net Income Guidance: Expected between $494 million and $514 million, with earnings per diluted share projected at $17.25 to $17.95.

4. Bad News, Challenges, or Points of Concern

• Cancellations, while improved, remain unpredictable and can significantly impact future bookings.
• The concentration of revenue from the top five and ten customers is a concern, as they represent 31% and 40% of revenue, respectively.
• The decline in metabolic program awards could signal a shift in business dynamics, potentially affecting future revenue streams.
• The company is cautious about predicting future cancellation rates, which could introduce volatility in revenue recognition.

5. Notable Q&A Insights

• The CEO confirmed that the growth in net awards was significantly driven by large programs in the metabolic sector, but oncology is regaining strength.
• There is uncertainty regarding the timing of when increased funding in biotech will translate into awards and backlog.
• The company has tightened its policies on backlog recognition, which has contributed to a higher backlog burn rate.
• The competitive landscape remains stable, with no significant changes in pricing or competition noted.
• The company expects a ramp-up in gross bookings in the second half of 2026, driven by a strong pipeline and reduced cancellations.

Overall, Medpace demonstrated solid financial performance in Q2 2026, with a strong outlook for the remainder of the year, despite some concerns regarding customer concentration and the unpredictability of cancellations.